Intellectual Property Rights (TRIPS) agreement, negotiated in 1994 and implemented in 2001, that committed them to adhere to patent protection along US lines. But as US military and economic dominance fades, so will TRIPS and its consequences.
The third factor is the rise of the 'open innovation' movement, which is making solid gains. ResearchGate, a Berlin-based information-sharing portal backed by Microsoft founder Bill Gates, has already attracted 2.9 million participants worldwide, most of them working in medicine or biology. And the open-access policy of the London-based Wellcome Trust, the world's largest biomedical research charity, was extended in April to require much Wellcome-funded work to be published with the least restrictive Creative Commons licence, allowing the papers' free dissemination by others -including for commercial gain.
The idea of open innovation is already well entrenched in information technology and other high-tech sectors, where companies find that they can meet customers' needs faster by building on each others' ideas. In many cases, broad cross-licensing agreements sweep patent obstacles out of the way. The biotechnology and pharmaceutical industries argue that medicines are a special case, and that without patent protection, no-one would bear the costs of obtaining regulatory approval for new drugs and devices. These regulatory barriers are so high in the first place, of course, because of industry's persistent and sometimes reckless attempts to circumvent them.
The patent-based model of innovation in biotechnology, as it stands, does bear occasional fruit in oncology, in which, as a biotech analyst once earnestly informed me, 'successful' drugs will extend a patient's life by six months, at US$10,000 a month. But our most pressing public-health needs are for new antibiotics and treatments for conditions such as Alzheimer's, which will never generate such windfall profits.
In genetic testing, Myriad's model of charging $3,000 for its test will be, it turns out, a bizarre one-off. The future public-health need will be for low-cost, multiple-gene tests, uninhibited by thickets of patents.
Efforts to develop an intellectual-property model that bypasses patents, such as the one proposed by the Biological Innovation for Open Society initiative in 2004 (see Nature 431, 494; 2004), have not progressed very far, and established models of innovation will not be overturned in a day. But they surely will evolve in ways that reflect the interests of the public, which is, after all, paying for the research, the diagnostics and the medicines. WORLD VIEWA personal take on events
